Skip to main content
  • 193 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Beauchamp LM, Orr GF, De Miranda P, Bumette T, Kre-nitsky TA (1992) Antiviral Chem Chemother 3:157–164

    CAS  Google Scholar 

  2. Krenitsky TA, Beauchchamp LM (1989) Eur Pat Appl, zit. nach CA 112:112048

    Google Scholar 

  3. De Miranda P, Burnette TC (1994) Drug Metab Dispos 22:55–59

    PubMed  Google Scholar 

  4. Burnette TC, De Miranda P (1994) Drug Metab Dispos 22:60–64

    PubMed  CAS  Google Scholar 

  5. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Pos-ner J (1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39:2759–2764

    Article  PubMed  CAS  Google Scholar 

  6. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ (1995) Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immuno-competent adults. Antimicrob Agents Chemother 39:1546–1553

    Article  PubMed  CAS  Google Scholar 

  7. Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral acitivity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754–772

    Article  PubMed  CAS  Google Scholar 

  8. Glaxo Wellcome, Hoechst (1995) Fachinformation Valtrex

    Google Scholar 

  9. Stahlmann R, Chahoud I, Thiel R, Klug S, Förster C (1997) The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studies. Reprod Toxicol 11:1–7

    Article  PubMed  CAS  Google Scholar 

  10. Bialer M, Haj-Yehia A, Barzaghi Pisani F, Perucca E (1990) Pharmacokinetics of a valpromide isomer, valnoc-tamide, in healthy subjects. Eur J Clin Pharmacol 38:289–291

    Article  PubMed  CAS  Google Scholar 

  11. Haj-Yehia A, Bialer M (1988) Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 77:831–834

    Article  PubMed  CAS  Google Scholar 

  12. Pisani F, Fazio A, Artesi C, Oteri G, Spina E, Tomson T, Perucca E (1992) Impairment of carbamazepine-10,11-ep-oxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. Br J Clin Pharmacol 34:85–87

    Article  PubMed  CAS  Google Scholar 

  13. Verheij AA (1992) Coma door overdosering van valnoctamide. Ned Tijdschr Geneeskd 1992 Jun 13; 136(24): 1177

    PubMed  CAS  Google Scholar 

  14. Melissant CF, Vinks AA, Sleeboom HP (1992) Coma door overdosering van valnoctamide. Ned Tijdschr Geneeskd 136:793–794

    PubMed  CAS  Google Scholar 

  15. Freifelder M, Geiszier A, Stone G (1961) J Org Chem 26:203

    Article  CAS  Google Scholar 

  16. Bühlmayer P, Furet P, Criscione L, De Gasparo M, Whitebread S, Schmidlin T, Lattmann R, Wood J (1994) Bioorg Med Chem Lett 4:29–34

    Article  Google Scholar 

  17. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, De Gasparo M (1995) Car-diovasc Drug Rev 13:230–250

    Article  CAS  Google Scholar 

  18. Waldmeier F, Flesch G. Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M (1997) Xenobiotiea 27:59–71

    Article  CAS  Google Scholar 

  19. Sioufi A, Marfil F, Godbillon J (1994) J Liq Chromatogr 17:2179–2186

    Article  CAS  Google Scholar 

  20. Burell LM, Johnston CI (1997) Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease. Drugs and Aging 10:421–434

    Article  Google Scholar 

  21. Criscione L, De Gasparo M, Bühlmayer P, Whitebread S, Ramjoue HPR, Wood J (1993) Pharmacological profile of valsartan: a potent orally active, nonpeptide antagonist of the angiotensin II ATI-receptor subtype. Br J Pharmacol 110:761–771

    Article  PubMed  CAS  Google Scholar 

  22. Yamamoto S, Hayashi N, Kometani M, Nakao K (1997) Pharmacological profile of valsartan, a non-peptide angiotensin II typ 1 receptor antagonist. 5thcommunication: hemodynamic effects of valsartan in dog heart failure models. Arzneimittel-Forschung 47:630–634

    PubMed  CAS  Google Scholar 

  23. De Gasparo M, Whitebread S (1995) Binding of valsartan to mammalian angiotensin ATI receptors. Regulatory peptides 59:303–311

    Article  PubMed  Google Scholar 

  24. Markham A, Goa KL (1997) Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299–311

    Article  PubMed  CAS  Google Scholar 

  25. Zierhut W, Laurent D, Allegrini P, Bullock G, Cumin F, Whitebread S, De Gasparo M (1994) Comparison of the effects of angiotensin converting enzyme inhibition and ATI-blockade of left ventricular structure and functional in renal hypertensive rats as determined by magnetic resonance imaging. Eur Heart J 15(Suppl):428

    Article  Google Scholar 

  26. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S (1997) Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-coverting enzyme inhibitor, lisinopril. J Human Hypertension 11:483–489

    Article  CAS  Google Scholar 

  27. Flesch G, Müller P, Lloyd P (1997) Absolute bioavaila-bility and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52:115–120

    Article  PubMed  CAS  Google Scholar 

  28. Bindschedler M, Degen P, Flesch G, De Gasparo M, Preiswerk G (1997) Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furose-mide. Eur J Clin Pharmacol 52:371–378

    Article  PubMed  CAS  Google Scholar 

  29. Czendlik CH, Sioufi A, Preiswerk G, Howald H (1997) Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol 52:451–459

    Article  PubMed  CAS  Google Scholar 

  30. Jung F, Kuy L, Poethke W, Pohloudek-Fabini R et al. (1969) Kommentar zum Deutschen Arzneibuch, 7. Ausgabe, Bd. VI, Akademieverlag, Berlin

    Google Scholar 

  31. Bricout J (1978) Ann Nutr Aliment 32:947–955, zit. nach CA (1979) 90:136161

    PubMed  CAS  Google Scholar 

  32. Thielemann H (1980) Sci Pharm 48:389–390

    CAS  Google Scholar 

  33. Packler KGR, Matlok F, Gremiich HU (1988) Merck FT-IR Atlas, VCH Verlagsgesellschaft, Weinheim, S. 607

    Google Scholar 

  34. Drugs Fut (1988) 13(9):839-840

    Google Scholar 

  35. Schweizer E, Thielen RJ, Frazer A (1997) Exp Opin luvest Drags 6:65–78

    Article  CAS  Google Scholar 

  36. Holliday SM, Benfield P (1995) Drugs 49:280–294

    Article  PubMed  CAS  Google Scholar 

  37. Morton WA, Sonne SC, Verga MA (1995) The Annals of Pharmacotherapie 29:387–395

    CAS  Google Scholar 

  38. Andrews JM, Ninan PT, Nemeroff CB (1996) Depression 4:48–56

    Article  PubMed  CAS  Google Scholar 

  39. Thase ME (1996) J Clin Psychopharmacol 16 (Suppl 2):10S–18S

    Article  PubMed  CAS  Google Scholar 

  40. Kelsey JE (1996) J Clin Psychopharmacol 16 (Suppl 2):21S–26S

    Article  PubMed  CAS  Google Scholar 

  41. Ballenger JC (1996) J Clin Psychpharmacol 16 (Suppl 2):29S–35S

    Article  CAS  Google Scholar 

  42. Ereshefsky L (1996) J Clin Psychopharmacol 16 (Suppl 2):37S–50S

    Article  PubMed  CAS  Google Scholar 

  43. Rudolph RL, Derivan AT (1996) J Clin Psychopharmacol 16(Suppl 2):54S–59S

    Article  PubMed  CAS  Google Scholar 

  44. Ellingrod VL, Perry PJ (1994) Am J Hosp Pharm 51:3033–3046

    PubMed  CAS  Google Scholar 

  45. Goldberg RJ (1997) Drags-Aging 11:119–131

    Article  CAS  Google Scholar 

  46. Dierick M (1997) Eur Psychiatry 12 (Suppl 4):307–313

    Article  Google Scholar 

  47. Preskorn S (1997) Eur Psychiatry 12 (Suppl 4):285–294

    Article  Google Scholar 

  48. Dinan TG, Burnett F (1997) J Serotonin Res 3/4:203–221

    Google Scholar 

  49. Scott MA, Shelton PS, Gattis W (1996) Pharmakotherapie 16:352–365

    CAS  Google Scholar 

  50. Rickeis K, Derivan A, Entsuah R, Miska S, Rudolph R (1995) Depression 3:146–153

    Article  Google Scholar 

  51. Taft DR, Lyer GR, Behar L, DiGregorio RV (1997) Drag Metab Dispos 25:1215–1218

    CAS  Google Scholar 

  52. Malizia AL, Melichar JM, Brown DJ, Gunn RN, Reynolds A, Jones T, Nutt DJ (1997) J Psychopharmacol 11:279–281

    Article  PubMed  CAS  Google Scholar 

  53. Ball SE, Ahern D, Scatina J, Kao J (1997) Br J Clin Pharmacol 43:619–626

    Article  PubMed  CAS  Google Scholar 

  54. Salin-Pascual RJ, Moro-Lopez ML (1997) Psychophar-makologie 129:295–296

    Article  CAS  Google Scholar 

  55. Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kiev A, Patrick R (1994) J Clin Psychopharmacol 14:322–329

    Article  PubMed  CAS  Google Scholar 

  56. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA (1994) Clin Pharmacol Ther 56:14–21

    Article  PubMed  CAS  Google Scholar 

  57. Tominaga N, Yo E, Ogawa H, Yamashita S, Yabuuchi Y, Nakagawa K (1984) Chem Pharm Bull 32:2100–2110

    Article  PubMed  CAS  Google Scholar 

  58. Shimizu T, Osumi T, Niimi K, Nakagawa K (1984) Arz-neim Forsch 34:334–341

    CAS  Google Scholar 

  59. Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA, et al. (1988) Cyclic AMP-dependent and cyclic AMP-Indepen-dent actions of a novel cardiotonic agent, OPC-8212. Nau-nyn Schmiedebergs Arch Pharmacol 338:692–698

    Article  CAS  Google Scholar 

  60. Yatani A, Imoto Y, Schwartz A, Brown AM (1989) New positive inotropic agent OPC-8212 modulates single Ca2+ Channels in ventricular myoeytes of guinea pig. J Cardio-vasc Pharmacol 13, 812–819

    Article  CAS  Google Scholar 

  61. Lathrop DA, Nanasi PP, Schwartz A, Varro A (1993) Ionic basis for OPC-8212-induced increases in action potential duration in isolated rabbit, guinea pig and human ventricular myocytes. Eur J Pharmacol 240:127–137

    Article  PubMed  CAS  Google Scholar 

  62. Packer M (1993) The development of positive inotropic agents for chronic heart failure: have we gone astray? J Am Cardiol 22 (4 Suppl A):119A–126A

    Article  CAS  Google Scholar 

  63. Itoh H, Kusagawa M, Shimomura A, Suga T, et al. (1993) Ca2+(-)dependent and Ca2+(-)independent vasorelaxati-on induced by cardiotonic phosohodiesterase inhibitors. Eur J Pharmacol 240:57–66

    Article  PubMed  CAS  Google Scholar 

  64. Asanoi H, Sasyama S, Kameyama T, Ishizaka S, et al. (1989) Sustained inotropic effects of a new cardiotonic agent OPC-8212 in patients with chronic heart failure. Clin Cardiol 12:133–138

    Article  PubMed  CAS  Google Scholar 

  65. OPC-8212 Multicenter Research Group (1990) A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardio-vasc Drugs Ther 4:419–425

    Article  Google Scholar 

  66. Katz AM (1995) Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol 18(9 Suppl 4):IV36–IV44

    Article  PubMed  CAS  Google Scholar 

  67. Shioi T, Mastsumori A, Matsui S, Sasayama S (1994) Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and mon-cytic cell line. Life Sci 54:PL11–PL16

    Article  PubMed  CAS  Google Scholar 

  68. Matsumori A, Shioi T, Yamada T, Matsui S (1994) Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89:955–958

    Article  PubMed  CAS  Google Scholar 

  69. Oyaizu N, McCloskey TW, Than S, Pahwa S (1996) Inhibition of CD4 cross-linking-induced lymphocytes apop-tosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Blood 87:2361–2368

    PubMed  CAS  Google Scholar 

  70. Sato Y, Matsumori A, Sasayama S (1995) Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J Mol Cell Cardiol 27:2265–2273

    Article  PubMed  CAS  Google Scholar 

  71. Matsui S, Matsumori A, Matoba Y, Uchida A, et al. (1994) Treatement of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 94:1212–1217

    Article  PubMed  CAS  Google Scholar 

  72. Hattori Y, So S, Hattori S, Kasai K, et al. (1995) Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardio-vasc Res 30:187–192

    CAS  Google Scholar 

  73. Feldman AM, Baughman KL, Lee WK, Gottlieb SH, et al. (1991) Usefulness of OPC-8212, a quinolinone derivate, for chronic congestive heart failure in patients with ischemic heart diesase or idiopathic dilated cardiomyopathy. Am J Cardiol 68:1203–1210

    Article  PubMed  CAS  Google Scholar 

  74. Feldman AM, Bristow MR, Pamly WW, Carson PE, et al. (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 329:149–155

    Article  PubMed  CAS  Google Scholar 

  75. Nony P, Boissel JP, Lievre M, Leizorovicz A, et al. (1994) Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analy-sis. Eur J Clin Pharmacol 46:191–196

    Article  PubMed  CAS  Google Scholar 

  76. Baughman K (1995) New medical therapies for advanced left ventricular dysfunction. Cardiol Clin 13:27–34

    PubMed  CAS  Google Scholar 

  77. Miyamoto G, Sasabe H, Tominaga N, Uegaki N, et al. (1988) Metabolism of a new positive inotropic agent, 3,4-dihy dro-6-[4-(3,4-dimethoxybenzoy 1)-1-piperaziny 1]-2(lH)-quinoline (OPC-8212) in rat, mouse, dog, monkey and human. Xenobiotica 18:1143–1155

    Article  PubMed  CAS  Google Scholar 

  78. Ohnishi A, Ishizaki T (1988) Pharmacokinetic profile of OPC-8212 in humans: a new, nonglycoside, inotropic agent. J Clin Pharmacol 28:719–726

    Article  PubMed  CAS  Google Scholar 

  79. Furusawa S, Ohashi Y, Asanoi H (1996) Vesnarinone-in-duced granulocytopenia: incidence in Japan and recommendations for safety. J Clin Pharmacol 36:477–481

    Article  PubMed  CAS  Google Scholar 

  80. Bertolet BD, White BG, Pepine CJ (1994) Neutropenia occuring during treatment with vesnarinone (OPC-8212). Am J Cardiol 74:968–970

    Article  PubMed  CAS  Google Scholar 

  81. Uetrecht JP, Zahid N, Whiltfield D (1994) Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 270:865–872

    PubMed  CAS  Google Scholar 

  82. Uetrecht JP (1995) Myeloperoxidase as a generator of drug free radicals. Biochem Soc Symp 61:163–170

    PubMed  CAS  Google Scholar 

  83. Mar31, S. 102

    Google Scholar 

  84. Drugs Fut (1984) 9(4):283-284

    Google Scholar 

  85. Araki T, Kato H, Nagaki S et al (1997) Mech Ageing Dev 95:13–29

    Article  PubMed  CAS  Google Scholar 

  86. Araki T, Kogure K (1989) Mol Chem Neuropath 11:33–43

    Article  CAS  Google Scholar 

  87. Lörincz C, Szasz K, Kisfaludy L (1976) Arzneim Forsch 26:1907

    Google Scholar 

  88. Kuge Y (1994) Synth Commun 24:759

    Article  CAS  Google Scholar 

  89. Kiss B, Karpati E (1996) Acta Pharm Hung 66:213–24

    PubMed  CAS  Google Scholar 

  90. Quevauviller A et al (1966) Ann Pharm Fr 24:39–41

    PubMed  CAS  Google Scholar 

  91. Woodward RB et al. (1945) J Am Chem Soc 67:860–875

    Article  CAS  Google Scholar 

  92. Cosnier D, Cheucle M, Rispat G, et al. (1977) Influence of hypercapnia on the cerebrovascular activities of some drugs in the treatment of cerebral ischemia. Arzneimittelf. 27:1566–1569

    CAS  Google Scholar 

  93. Hünermann B, Felix R, Wesener K, et al. (1973) Einfluß von Viquidil auf die Hirnzirkulation. Arzneimittelf. 23:1074–1076

    Google Scholar 

  94. Mar 31, S. 1767

    Google Scholar 

  95. Uzan A, Guérémy C (1972) Viquidil: étude du métabolisme par méthode isotopique. II. Arzneimittelf. 22:1341–1346

    CAS  Google Scholar 

  96. Uzan A, Guérémy C (1974) Viquidil: étude du métabolisme par méthode isotopique. III. Arzneimittelf. 24:34–39

    CAS  Google Scholar 

  97. Prous J, Graul A, Castaner J (1994) Drugs Fut 19:457–459

    Google Scholar 

  98. Raeymaekers AHM, Freyne EJE, Van Gelder JLH, Verier MG (Janssen Pharm NV) AU 8816537, EP 293978, JP 88316775, zit. nach Lit. 1

    Google Scholar 

  99. Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M (1994) Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54(22):5875–5881

    PubMed  CAS  Google Scholar 

  100. De Coster R, Tuman RW, Bowden CR, Bruynseels J, Vanderpas H, Van Rooy P, Anery WK, Janssen PA (1989) Aromatase inhibition by R 76713: experimental and clinical pharmacology. J Steroid Biochem 34(1–6):427–430

    PubMed  Google Scholar 

  101. Wouters W, Snoeck E, De Coster R, Vorozole (1994) A specific nonsteroidal aromatase inhibitor. Breast Cancer Res Treat 30(1):89–94

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

von Bruchhausen, F. et al. (1999). V. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-58388-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-58388-9_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63569-4

  • Online ISBN: 978-3-642-58388-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics